Literature DB >> 21902893

A clinical analysis of primary testicular diffuse large B-cell lymphoma in China.

Bing Cao1, Dong-Mei Ji, Xiao-Yan Zhou, Ti-Ping Zhao, Ye Guo, Zhong-Hua Wang, Jun-Ning Cao, Xi-Chun Hu, Xiao-Nan Hong.   

Abstract

The objective of this study was to analyze the clinical behavior and treatment policy of patients with primary testicular diffuse large B-cell lymphoma by retrospective analysis of 32 patients at our institute. All patients underwent orchidectomy. Anthracycline-based chemotherapy was administered to 27 patients (84·38%), six of whom also received rituximab; prophylactic intrathecal chemotherapy was given to seven patients (21·88%); and eight patients (25%) received prophylactic scrotal radiotherapy. Thirteen patients had relapse, among whom 12 cases were extranodal recurrences. Seven patients had central nervous system involvement, and four patients relapsed in the contralateral testis. The presence of B symptoms, poor Eastern Cooperative Oncology Group performance status, left testicular involvement, central nervous system involvement, and first relapse within 1 year were associated with worse progression-free survival using univariate analysis. Poor Eastern Cooperative Oncology Group performance status, left testicular involvement, and surgery alone were negative prognostic factors for overall survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21902893     DOI: 10.1179/102453311X13085644680221

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  7 in total

1.  Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution.

Authors:  Ryouji Tokiya; Eisaku Yoden; Kei Konishi; Nobuhiko Kamitani; Junichi Hiratsuka; Risa Koresawa; Tadashi Hirose; Fuminori Sano; Hirotoshi Tokunaga; Toshinori Kondo; Hideho Wada; Takashi Sugihara
Journal:  Int J Hematol       Date:  2017-06-13       Impact factor: 2.490

2.  Three prognostic factors influence clinical outcomes of primary testicular lymphoma.

Authors:  Yu Wang; Zhi-Ming Li; Jia-Jia Huang; Yi Xia; Heng Li; Ya-Jun Li; Ying-Jie Zhu; Wei Zhao; Xi-Ya Xia; Wen-Xiao Wei; Hui-Qiang Huang; Tong-Yu Lin; Wen-Qi Jiang
Journal:  Tumour Biol       Date:  2012-09-11

3.  Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival.

Authors:  Kunimoto Ichikawa; Masaaki Noguchi; Michiaki Koike; Nanae Aritaka; Yasunobu Sekiguchi; Yoshitaka Sunami; Miyuki Tsutsui; Masaru Hosone; Takao Hirano; Akihiko Gotoh; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-08-02       Impact factor: 2.490

4.  Primary Diffuse large B-Cell lymphoma of testis: A single centre experience and review of literature.

Authors:  Kadabur Nagendrapp Lokesh; Vishwanath Sathyanarayanan; C Lakshmaiah Kuntegowdanahalli; T M Suresh; Lokanatha Dasappa; Govinda Babu K Kanakasetty
Journal:  Urol Ann       Date:  2014-07

5.  Prognostic Significance of LDH Ratio in Serum/Cerebral Spinal Fluid of Patients with Primary Testicular Diffuse Large B-Cell Lymphoma.

Authors:  Yi-Zhen Liu; Pan Luo; Cheng Liu; Kai Xue; Jia Jin; Zu-Guang Xia; Xiao-Jian Liu; Qun-Ling Zhang; Jun-Ning Cao; Xiao-Nan Hong; Fang-Fang Lv
Journal:  Onco Targets Ther       Date:  2019-12-02       Impact factor: 4.147

6.  Primary Testicular Lymphoma with Central Nervous System Relapse Was Successfully Treated by a Chemo-Free Regimen: A Case Report and Literature Review.

Authors:  Zheng Yan; Shuna Yao; Yuanyuan Wang; Yanyan Liu; Zhihua Yao
Journal:  Cancer Manag Res       Date:  2021-12-31       Impact factor: 3.989

7.  The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience.

Authors:  Run-Zhuo Ma; Lei Tian; Li-Yuan Tao; Hui-Ying He; Min Li; Min Lu; Lu-Lin Ma; Hui Jiang; Jian Lu
Journal:  Asian J Androl       Date:  2018 Nov-Dec       Impact factor: 3.285

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.